Skip to content

Cannabis research published in 2005

25 studies whose primary subject is cannabis were published in 2005, down from 27 in 2004. Newest first. Back to the cannabis overview

Studies

Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure.

Journal of Neuroscience December 14, 2005 Susana Mato, David Robbe, Nagore Puente et al.

Alterations of long-term synaptic plasticity have been proposed to participate in the development of addiction. To preserve synaptic functions, homeostatic processes must be engaged after exposure to abused drugs. At the mouse cortico-accumbens synapses, a single in vivo injection of Delta9-tetrahydrocannabinol (THC) suppresses endocannabinoid-mediated long-term depression. Using biochemical...

Personality Characteristics of Adolescents with Hallucinogen, Methamphetamine, and Cannabis Dependence: A Comparative Study

Journal of Child & Adolescent Substance Abuse December 5, 2005 Glen A. Palmer, Doyle D. Daiss 14 citations

ABSTRACT A comparison of personality factors on scales of the Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-A) was conducted with a sample of adolescents referred to a residential substance abuse treatment program. A total of sixty adolescents identified with hallucinogen (n = 20), cannabis (n = 20), or methamphetamine (n = 20) as their drug of choice participated in the study....

DOI: 10.1300/j029v15n01_03 (opens in new tab) Hallucinogen Methamphetamine Clinical psychology Personality +2

Two cases of "cannabis acute psychosis" following the administration of oral cannabis

BMC Psychiatry December 1, 2005 Bernard Favrat, Annick Ménétrey, Marc Augsburger et al.

Abstract Background Cannabis is the most commonly used illegal drug and its therapeutic aspects have a growing interest. Short-term psychotic reactions have been described but not clearly with synthetic oral THC, especially in occasional users. Case presentations We report two cases of healthy subjects who were occasional but regular cannabis users without psychiatric history who developed...

Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases

The British Journal of Psychiatry November 30, 2005 Mikkel Arendt, Raben Rosenberg, Leslie Foldager et al. 258 citations

BACKGROUND: Few studies have examined samples of people with cannabis-induced psychotic symptoms. AIMS: To establish whether cannabis-induced psychotic disorders are followed by development of persistent psychotic conditions, and the timing of their onset. METHOD: Data on patients treated for cannabis-induced psychotic symptoms between 1994 and 1999 were extracted from the Danish Psychiatric...

Cannabis--psychosis pathway independent of other types of psychopathology.

Schizophrenia Research November 15, 2005 Robert F Ferdinand, Jan Van der Ende, Ilja Bongers et al.

To investigate if associations between cannabis use and psychotic symptoms occur independently, or occur as a consequence of previous-other types of-psychopathology. A 14-year follow-up study of 1580 initially 4- to 16-year-olds who were drawn randomly from the Dutch general population was conducted. At initial assessment, psychopathology was assessed with the Child Behavior Checklist. Across...

SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.

Behavioural Pharmacology September 2005 Lance R Mcmahon, M R Amin, Charles P France

The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC). This study examined the effects of SR 141716A on the rate-decreasing, hypothermic and discriminative stimulus effects of delta9-THC in rhesus monkeys. In monkeys (n=4) responding...

Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids

Behavioural Pharmacology September 1, 2005 Aaron B Ilan, Alan Gevins, Michael J. Coleman et al. 165 citations

This study investigated the contribution of different cannabinoids to the subjective, behavioral and neurophysiological effects of smoked marijuana. Healthy marijuana users (12 men, 11 women) participated in four sessions. They were randomly assigned to a low or a high delta9-tetrahydrocannabinol group (THC; 1.8% versus 3.6%). In the four sessions under blinded conditions subjects smoked...

The P3 in ‘ecstasy’ polydrug users during response inhibition and execution

Journal of Psychopharmacology September 1, 2005 Alex Gamma, Daniel Brandeis, Ruven Brandeis et al. 36 citations

Substance abuse and associated externalizing disorders are characterized by behavioural disinhibition and low impulse control, with reduced neural inhibition postulated to be the common underlying brain mechanism. The P3 component of event-related potentials (ERPs) is a widely used neurophysiological measure thought to reflect inhibitory brain processes, but as yet has not been assessed in...

Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats.

Neuropsychopharmacology August 2005 June M Young, Iain S. Mcgregor, Paul E Mallet

3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') and cannabis are two of the most commonly used illicit drugs in the western world, and are often used in combination. Very little research has examined their effect on cognitive function or behavior when combined, The present study used a double Y-maze task to examine the acute effect of MDMA and delta9-tetrahydrocannabinol (THC, the principal...

Assessment of Driving Capability Through the Use of Clinical and Psychomotor Tests in Relation to Blood Cannabinoids Levels Following Oral Administration of 20 mg Dronabinol or of a Cannabis Decoction Made with 20 or 60 mg Δ9-THC*

Journal of Analytical Toxicology July 1, 2005 Annick Ménétrey, Marc Augsburger, Bernard Favrat et al. 89 citations

Delta(9)-Tetrahydrocannabinol (THC) is frequently found in the blood of drivers suspected of driving under the influence of cannabis or involved in traffic crashes. The present study used a double-blind crossover design to compare the effects of medium (16.5 mg THC) and high doses (45.7 mg THC) of hemp milk decoctions or of a medium dose of dronabinol (20 mg synthetic THC, Marinol on several...

Hallucinogen persisting perception disorder after psilocybin consumption: a case study

European Psychiatry June 18, 2005 Marie-Laure Espiard, Laurent Lecardeur, Pascale Abadie et al. 61 citations

Abstract The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucinogen persisting perception disorder (HPPD). Perceptual disturbances may last for 5 years or more and represent a real psychosocial distress. We reported here a case of a 18-year-old young man presenting HPPD after a mixed intoxication with psylocibin...

Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Psychopharmacology June 2005 Marcello Solinas, Steven R Goldberg

Many behavioral effects of delta-9-tetrahydrocannabinol (THC), including its discriminative-stimulus effects, are modulated by endogenous opioid systems. To investigate opioid receptor subtypes involved in the discriminative effects of THC. Rats trained to discriminate 3 mg/kg i.p. of THC from vehicle using a two-lever operant drug-discrimination procedure, were tested with compounds that bind...

Neural substrates of faulty decision-making in abstinent marijuana users.

Neuroimage June 2005 Karen I Bolla, Dana A Eldreth, John A Matochik et al.

Persistent dose-related cognitive decrements have been reported in 28-day abstinent heavy marijuana (MJ) users. However, the neural substrates of these decrements in cognitive performance are not known. This study aimed to determine if 25-day abstinent MJ users show persistent dose-related alterations in performance and brain activity using PET H(2)(15)O during the Iowa Gambling Task-IGT (a...

Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.

Human psychopharmacology June 2005 R M Milani, A C Parrott, F Schifano et al.

Cannabis is one of the most common 'co-drugs' for ecstasy users. The aim of the present study was to explore self-reported psychobiological problems in ecstasy polydrug users in relation to their pattern of cannabis use. Two hundred and eighty ecstasy polydrug users were allocated into five cannabis groups according to the frequency of their cannabis use. The control group comprised 121...

Cannabis use and outcome of recent onset psychosis

European Psychiatry June 1, 2005 Anton Grech, Jim van Os, Peter B. Jones et al.

AbstractPurposeTo test the hypothesis that recent onset psychotic patients who use cannabis will have psychotic symptoms that are more severe and more persistent than those who do not use cannabis.Subjects and methodsWe carried out a 4-year follow-up study of a cohort of 119 patients with recent onset of psychosis. The patients were divided into four groups according to duration of cannabis...

Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users.

Psychopharmacology May 2005 M Rizzo, C T J Lamers, C G Sauer et al.

Illicit drug use can increase driver crash risk due to loss of control over vehicle trajectory. This study asks, does recreational use of +/-3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) and tetrahydrocannabinol (THC; marijuana) impair cognitive processes that help direct our safe movement through the world? This study assesses the residual effects of combined MDMA/THC use, and of THC use...

THE CANNABIS AND PSYCHOSIS CONNECTION QUESTIONED: A COMMENT ON FERGUSSON ET AL. 2005

Addiction April 22, 2005 B Mirken, Mitch Earleywine 10 citations

Fergusson and colleagues assert that their results from a New Zealand cohort ‘add to the growing body of evidence that regular cannabis use may increase risks of psychosis’[1]. In fact, their study raises more questions than it answers. One obvious question is raised by their use of ten items from Symptom Checklist 90 as the only assessment tool for symptoms of psychosis. The items assessed...

Acute marijuana effects on human risk taking.

Neuropsychopharmacology April 2005 Scott D Lane, Don R Cherek, Oleg V Tcheremissine et al.

Previous studies have established a relationship between marijuana use and risky behavior in natural settings. A limited number of laboratory investigations of marijuana effects on human risk taking have been conducted. The present study was designed to examine the acute effects of smoked marijuana on human risk taking, and to identify behavioral mechanisms that may be involved in drug-induced...

Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation.

Brain research. Cognitive brain research April 2005 Staci A Gruber, Deborah A Yurgelun-Todd

Neuropsychological investigations of substance abusers have reported impairments on tasks mediated by the frontal executive system, including functions associated with behavioral inhibition and decision making. The higher order or executive components which are involved in decision making include selective attention and short term storage of information, inhibition of response to irrelevant...

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Biological Psychiatry March 15, 2005 Deepak Cyril D'Souza, Walid Michel Abi-Saab, Steven Madonick et al.

Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders. In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated...